Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-03
2006-10-03
Pak, Michael (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07115554
ABSTRACT:
The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
REFERENCES:
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 5602096 (1997-02-01), Goodearl et al.
patent: PCT/US89/00051 (1989-07-01), None
patent: PCT/US90/02697 (1990-11-01), None
patent: PCT/US91/02331 (1991-10-01), None
patent: PCT/US91/03443 (1991-12-01), None
patent: PCT/US92/00329 (1992-07-01), None
patent: PCT/WO92/12174 (1992-07-01), None
Benveniste et al., “Purification and characterization of a human T-Lymphocyte-derived glial growth-promoting factor” PNAS USA 82:3930-3934 (1985).
Berger et al., “Correlation of c-erbB-2 Gene Amplification and Protein Expression in Human Breast Carcinoma with Nodal Status and Nuclear Grading”,Cancer Research48:1238-1243, 1988.
Brockes et al., “Purification and Preliminary Characterization of a Glial Growth Factor from the Bovine Pituitary” J. Biol. Chem. 255:8374-8377 (1980).
Brockes et al., “The neuron as a source of mitogen”, Development In The Nervous System, Garrod and Feldman, eds., pp. 309-327 (1980).
Chan et al., “Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript”, Science, 254:1382-1385, 1991.
Davis et al., “Platelet-derived Growth Factors and Fibroblast Growth Factors Are Mitogens for Rat Schwann Cells” J. Cell Biol. 110:1353-1360 (1990).
Davis et al., “Isolation and characterization of a new protein-specific activating factor from human ATL-2 cell conditioned medium” Biochem. Biophys. Res. Communications 179:1536-1542 (1991).
Dobashi et al., “Characterization of a neu/c-erbB-2 protein-specific activating factor” PNAS USA 88:8582-8586 (1991).
Florini et al., “Effects of Growth Factors on Myogenic Differentiation”, American J. Of Physiology 256:C701-C711.
Holmes et al., “Identification of Heregulin, a Specific Activator of p185erbB2” Science 256:1205-1210 (1992).
Huang et al., “Purification and Characterization of the new/erb B2 Ligand-Growth Factor from Bovine Kidney” J. Biol. Chem. 267:11508-11512 (1992).
Kimura et al., “Structure, expression and function of a schwannoma-derived growth factor” Nature 348:257-260 (1990).
Kraus et al., “Overexpression of the EGF receptor-related prroto-oncogen erbB-2 in human mammary tumor cell lines by different molecular mechanisms”, EMBO Journal 6:605-610, 1987.
Lemke et al., “Identification and Purification of Glial Growth Factor”, J. Neuroscience, 4:75-83 (1984).
Lemke et al., “An immunochemical approach to the purification and characterization of glial growth factor”, Monoclonal Antibodies To Neural Antigens, McKay et al., eds. 133-140 (1981).
Lupu et al., “Direct Interaction of a Ligand for the erbB2 Oncogene Product with the EGF Receptor and p185 erb2”, Science 249:1552-1555 (1990).
Lupu et al., “Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses” PNAS USA 89:2287-2291 (1992).
Marchionni et al., “Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system”, Nature 362:312-362, 1993.
Peles et al., “Isolation of the Neu/HER-2 Stimulatory Ligand: A 44 kd Glycoprotein That Induces Differentia-tion of Mammary Tumor Cells” Cell 69:205-216 (1992).
Peles et al., “Neu and its ligands: From an Oncogene to Neural Factors”, Bioessays 15:815-824, 1993.
Perantoni et al., “Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourcea”, PNAS USA, 84:6317-6321, 1987.
Slamon et al., “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene”, Science, 235:177-182, 1987.
Slamon et al., “Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer”, Science, 244:707-712, 1989.
Tarakhovsky et al., “A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages” Oncogene 6:2187-2196 (1991).
Tsuda et al., “Correlation between Long-Term Survival in Breast Cancer Patients and Amplification of Two Putative Oncogene-Coamplification Units: hst-1/int-2 and c-erbB-2/ear-1”, Cancer Research 49:3104-3108, 1989.
van de Vijver et al., “Amplification of the neu (c-erbB-2) Oncogene in Human Mammary Tumors is Relatively Frequence and Is Often Accompanied by Amplification of the Linked c-erb/A Oncogene”, Mol. Cellular Biology, 7:2019-2023, 1987.
Varley et al., “Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis”, Oncogene, 1:423-430, 1987.
Venter et al., “Overexpression of the c-erbB-2 Oncoprotein in Human Breast Carcinomas: Immunohistological Assessment Correlates with Gene Amplification”, 11:69-72, 1987.
Wen et al., “Neu Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit”, Cell 69:559-572 (1992).
Yarden et al., “Biochemical Analysis of the Ligand for the neu Oncogenic Receptor” Biochemistry 30:3543-3550 (1991).
Yarden et al., “Growth Factor Receptor Tyrosine Kinases”, Ann. Rev. Biochem. 57:443-478 (1988).
Yu et al., “Early mutation of the neu (erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage”, PNAS USA 88:9939-9943, 1991.
Zhou et al., “Association of Multiple Copies of the c-erbB-2 Oncogene with Spread of Breast Cancer”, Cancer Research, 47:6123-6125, 1987.
Markelonis et al., Dialog Medline, J. Neurochem. 39:315-20, 1982.
Markelonis et al., Dialog Medline, Dev. Biol. 89:353-61, 1982.
Markelonis et al., Dialog Medline, J. Neurochem. 37:95-9, 1981.
Markelonis et al., Dialog Medline, Exp. Neurol. 70:598-612, 1980.
Oh et al., Dialog Medline, J. Histochem. Cytochem. 29:1205-12, 1981.
Oh et al., Dialog Medline, PNAS USA 77:6922-5, 1980.
Falls et al.; “ARIA, a Protein That Stimulates Acetylcholine Receptor Synthesis, Is a Member of the Neu Ligand Family”, Cell, 72:810-815, 1993.
Brockes et al., “Assay and Isolation of Glial Growth Factor from the Bovine Pituitary”, Methods In Enzym. 147:217-225, 1987.
Jeong et al., Dialog Medline Abs., J. Neurobiol. 22:462-74, 1991.
Jessel et al., “Induction of acetylcholine receptors on cultured skeletal muscle by a factor extracted from brain and spinal cord” PNAS USA 76:5397-5401, 1979.
Lentz, et al., “Partial purification and characterization of a nerve trophic factor regulating muscle acetylcholinesterase activity” Exper. Neurology 73:542-557, 1981.
Markelonis et al., “Purification of sciatin using affinity chromatography on concanavalin A-Agarose” J. Neurochemistry 37:95-99, 1981.
Markelonis et al., Dialog Medline Abs. J. Cell Bio. 100:8-17, 1985.
Markelonis et al., Dialog Medline Abs. J. Biol. Chem. 255:8967-70, 1980.
Markelonis et al., Dialog Medline Abs. Exp. Neurol. 58:285-95, 1978.
Oh, “Neurotrophic effects of sciatic nerve extracts on muscle development in culture” Exp. Neurology 50:376-386, 1976.
Oh et al., Dialog Medline Abs. Dev. Biology 127:88-98, 1988.
Oh et al., Dialog Medline Abs. J. Neuros. Res. 8:535-45, 1982.
Oh et al., Dialog Medline Abs. Exp. Neurol. 67:646-54, 1980.
Oh et al., Dialog Medline Abs. Science 200:337-9, 1978.
Oh et al., Dialog Medline Abs. Exp. Neurol. 46:432-8, 1975.
Podleski et al., “Nerve extract induces increase and redistri
Gwynne David I.
Marchionni Mark
Sklar Robert
Acorda Therapeutics, Inc.
Bieker-Brady Kristina
Clark & Elbing LLP
Pak Michael
LandOfFree
Methods of increasing myotube formation or survival or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of increasing myotube formation or survival or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of increasing myotube formation or survival or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682216